NCT01175343: RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
|
|
| Completed | 2 | 45 | US, Canada | Gamma-Secretase Inhibitor RO4929097, RO4929097, Laboratory Biomarker Analysis | National Cancer Institute (NCI) | Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer | 10/12 | 08/15 | | |
